UK-based Balderton Capital has led a $30m series D funding round for the Swiss health tech firm Sophia Genetics. The company is developing an artificial intelligence platform that will allow doctors to identify and treat patients with rare genetic diseases. It claims the overall patient data collected will also lead to better diagnosis of others. A number of other companies are looking to use AI technology in the healthcare sector, such as DeepMind Technologies, which is working with the British National Health Service to implement a patient care management system relying on machine learning.
UK-based Balderton Capital has led a $30m series D funding round for the Swiss health tech firm Sophia Genetics. The company's SOPHiA AI system is used to analyse patients' DNA to diagnose illnesses and gain a better understanding of their health needs. It claims the overall patient data collected will also lead to better diagnosis of others. A number of other companies are looking to use AI technology in the healthcare sector, such as DeepMind Technologies, which is working with the British National Health Service to implement a patient care management system relying on machine learning.